Sensitivity | Specificity | PPV | NPV | PLR | NLR | AUC | 95% CI | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Margin status | ||||||||||||
Margin(+) | 12/52 | 23.08 (13.72–36.13) | 299/333 | 89.79 (86.07–92.6) | 12/46 | 26.09 (15.6–40.26) | 299/339 | 88.2 (84.33–91.21) | 2.26 (1.253–4.076) | 0.857 (0.735–0.999) | 0.5643 | (0.5043–0.6244) |
Exo(+), Endo(-) | 3/52 | 5.77 (1.98–15.64) | 327/333 | 98.2 (96.13–99.17) | 3/9 | 33.33 (12.06–64.58) | 327/376 | 86.97 (83.19–90) | 3.202 (0.826–12.41) | 0.96 (0.896–1.028) | ||
Exo(-), Endo(+) | 9/52 | 17.31 (9.38–29.73) | 310/333 | 93.09 (89.85–95.35) | 9/32 | 28.13 (15.56–45.37) | 310/353 | 87.82 (83.99–90.83) | 2.506 (1.228–5.112) | 0.888 (0.782–1.009) | ||
Both (+) | 0/52 | 0 (0–6.88) | 328/333 | 98.5 (96.53–99.36) | 0/5 | 0 (0–43.45) | 328/380 | 86.32 (82.49–89.41) | 1.015 (1.002–1.029) | |||
HPV status (postop) | ||||||||||||
HPV+ | 39/52 | 75 (61.79–84.77) | 254/333 | 76.28 (71.42–80.53) | 39/118 | 33.05 (25.22–41.95) | 254/267 | 95.13 (91.85–97.13) | 3.161 (2.466–4.053) | 0.328 (0.204–0.527) | 0.7564 | (0.697–0.8201) |
HPV (+) and margin(+) | 6/52 | 11.54 (5.4–22.97) | 324/333 | 97.3 (94.94–98.57) | 6/15 | 40 (19.82–64.25) | 324/370 | 87.57 (83.81–90.55) | 4.269 (1.585–11.499) | 0.909 (0.823–1.005) | 0.5442 | (0.4995–0.5889) |
HPV (+) and margin (-) | 33/52 | 63.46 (49.87–75.2) | 263/333 | 78.98 (74.28–83.01) | 33/103 | 32.04 (23.81–41.56) | 263/282 | 93.26 (89.72–95.64) | 3.019 (2.252–4.047) | 0.463 (0.322–0.665) | ||
HPV (-) and margin (+) | 6/52 | 11.54 (5.4–22.97) | 308/333 | 92.49 (89.15–94.86) | 6/31 | 19.35 (9.19–36.28) | 308/354 | 87.01 (83.1–90.11) | 1.537 (0.662–3.566) | 0.956 (0.863–1.06) | ||
HPV (-) and margin (-) | 7/52 | 13.46 (6.68–25.27) | 104/333 | 31.23 (26.49–36.4) | 7/236 | 2.97 (1.44–5.99) | 104/149 | 69.8 (62.01–76.6) | 0.196 (0.098–0.391) | 2.771 (2.287–3.358) |